...
机译:MTORC1抑制剂evolimus和免疫调节药物的新组合和免疫调节药物Lenalidomide在重新治疗重复淋巴瘤的患者中产生耐用的反应
Department of Hematology Oncology Mayo Clinic Arizona;
Department of Hematology Oncology Mayo Clinic Jacksonville;
Department of Research Biostatistics Mayo Clinic Arizona;
Department of Research Biostatistics Mayo Clinic Arizona;
Department of Research Biostatistics Mayo Clinic Arizona;
Department of Hematology Oncology Mayo Clinic Arizona;
Department of Hematology Mayo Clinic;
Department of Hematology Mayo Clinic;
Department of Hematology Oncology Mayo Clinic Arizona;
Department of Hematology Oncology Mayo Clinic Arizona;
Department of Hematology Mayo Clinic;
Department of Hematology Mayo Clinic;
Department of Hematology Mayo Clinic;
Department of Hematology Mayo Clinic;
Department of Hematology Mayo Clinic;
Department of Hematology Oncology Mayo Clinic Arizona;
Combination Therapy; Overall response rate; Phase I; Phase II; Relapsed and refractory lymphoma;
机译:MTORC1抑制剂evolimus和免疫调节药物的新组合和免疫调节药物Lenalidomide在重新治疗重复淋巴瘤的患者中产生耐用的反应
机译:mTORC1抑制剂依维莫司在体外具有抗肿瘤活性,并对复发的T细胞淋巴瘤患者产生肿瘤反应
机译:来那度胺加利妥昔单抗可对复发或顽固性惰性非霍奇金淋巴瘤患者产生持久的临床反应。
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:mTORC1抑制剂依维莫司在体外具有抗肿瘤活性并在复发性T细胞淋巴瘤患者中产生肿瘤反应
机译:MTORC1抑制剂Everolimus体外具有抗肿瘤活性,并在复发的T细胞淋巴瘤患者中产生肿瘤反应